Amicus Therapeutics, Inc. (0HF9.L)
USD 9.86
(-1.0%)
USD 9.86
(-1.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 777.88 Million USD | 7.42% |
| 2022 | 724.16 Million USD | -19.99% |
| 2021 | 905.14 Million USD | 2.1% |
| 2020 | 886.52 Million USD | 4.27% |
| 2019 | 850.2 Million USD | 7.63% |
| 2018 | 789.95 Million USD | 25.98% |
| 2017 | 627.02 Million USD | -39.53% |
| 2016 | 1.03 Billion USD | 14.14% |
| 2015 | 908.38 Million USD | 332.63% |
| 2014 | 209.96 Million USD | 64.6% |
| 2013 | 127.56 Million USD | 15.87% |
| 2012 | 110.08 Million USD | 57.73% |
| 2011 | 69.79 Million USD | -37.99% |
| 2010 | 112.55 Million USD | 31.84% |
| 2009 | 85.37 Million USD | -33.71% |
| 2008 | 128.77 Million USD | -22.94% |
| 2007 | 167.09 Million USD | 180.15% |
| 2006 | 59.64 Million USD | 108.04% |
| 2005 | 28.66 Million USD | 0.0% |
| 2003 | 501 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 749.48 Million USD | 3.84% |
| 2024 Q1 | 721.78 Million USD | -7.21% |
| 2023 Q1 | 700.51 Million USD | -3.27% |
| 2023 Q2 | 730.09 Million USD | 4.22% |
| 2023 Q3 | 764.08 Million USD | 4.66% |
| 2023 Q4 | 777.88 Million USD | 1.81% |
| 2023 FY | 777.88 Million USD | 7.42% |
| 2022 Q4 | 724.16 Million USD | -4.66% |
| 2022 Q2 | 800.58 Million USD | -3.19% |
| 2022 Q3 | 759.52 Million USD | -5.13% |
| 2022 Q1 | 826.93 Million USD | -8.64% |
| 2022 FY | 724.16 Million USD | -19.99% |
| 2021 Q3 | 956.67 Million USD | 21.58% |
| 2021 FY | 905.14 Million USD | 2.1% |
| 2021 Q2 | 786.89 Million USD | -2.86% |
| 2021 Q4 | 905.14 Million USD | -5.39% |
| 2021 Q1 | 810.03 Million USD | -8.63% |
| 2020 FY | 886.52 Million USD | 4.27% |
| 2020 Q1 | 738.34 Million USD | -13.16% |
| 2020 Q2 | 701.45 Million USD | -5.0% |
| 2020 Q3 | 900.54 Million USD | 28.38% |
| 2020 Q4 | 886.52 Million USD | -1.56% |
| 2019 Q3 | 882.29 Million USD | -3.89% |
| 2019 Q1 | 764.7 Million USD | -3.2% |
| 2019 FY | 850.2 Million USD | 7.63% |
| 2019 Q2 | 918.03 Million USD | 20.05% |
| 2019 Q4 | 850.2 Million USD | -3.64% |
| 2018 Q4 | 789.95 Million USD | -5.8% |
| 2018 Q3 | 838.58 Million USD | 1.54% |
| 2018 Q2 | 825.88 Million USD | -5.07% |
| 2018 Q1 | 870 Million USD | 38.75% |
| 2018 FY | 789.95 Million USD | 25.98% |
| 2017 Q1 | 993.38 Million USD | -4.19% |
| 2017 FY | 627.02 Million USD | -39.53% |
| 2017 Q4 | 627.02 Million USD | -7.9% |
| 2017 Q3 | 680.77 Million USD | -27.5% |
| 2017 Q2 | 938.96 Million USD | -5.48% |
| 2016 Q1 | 862.9 Million USD | -5.01% |
| 2016 Q3 | 918.18 Million USD | 0.46% |
| 2016 Q4 | 1.03 Billion USD | 12.92% |
| 2016 FY | 1.03 Billion USD | 14.14% |
| 2016 Q2 | 914 Million USD | 5.92% |
| 2015 Q1 | 192.61 Million USD | -8.26% |
| 2015 Q4 | 908.38 Million USD | -7.94% |
| 2015 Q3 | 986.69 Million USD | 144.28% |
| 2015 FY | 908.38 Million USD | 332.63% |
| 2015 Q2 | 403.91 Million USD | 109.7% |
| 2014 Q3 | 125.48 Million USD | 6.35% |
| 2014 Q4 | 209.96 Million USD | 67.32% |
| 2014 Q2 | 117.99 Million USD | 5.02% |
| 2014 FY | 209.96 Million USD | 64.6% |
| 2014 Q1 | 112.35 Million USD | -11.92% |
| 2013 Q3 | 69.1 Million USD | -16.07% |
| 2013 Q4 | 127.56 Million USD | 84.59% |
| 2013 Q1 | 93.21 Million USD | -15.33% |
| 2013 Q2 | 82.33 Million USD | -11.67% |
| 2013 FY | 127.56 Million USD | 15.87% |
| 2012 Q3 | 118.21 Million USD | 5.93% |
| 2012 Q2 | 111.59 Million USD | -7.62% |
| 2012 FY | 110.08 Million USD | 57.73% |
| 2012 Q1 | 120.8 Million USD | 73.08% |
| 2012 Q4 | 110.08 Million USD | -6.87% |
| 2011 Q2 | 90.28 Million USD | -11.96% |
| 2011 FY | 69.79 Million USD | -37.99% |
| 2011 Q4 | 69.79 Million USD | -11.5% |
| 2011 Q3 | 78.86 Million USD | -12.65% |
| 2011 Q1 | 102.55 Million USD | -8.89% |
| 2010 Q4 | 112.55 Million USD | 76.52% |
| 2010 FY | 112.55 Million USD | 31.84% |
| 2010 Q2 | 74.88 Million USD | -15.03% |
| 2010 Q3 | 63.76 Million USD | -14.85% |
| 2010 Q1 | 88.13 Million USD | 3.24% |
| 2009 FY | 85.37 Million USD | -33.71% |
| 2009 Q4 | 85.37 Million USD | -13.67% |
| 2009 Q3 | 98.89 Million USD | -9.0% |
| 2009 Q2 | 108.67 Million USD | -6.62% |
| 2009 Q1 | 116.37 Million USD | -9.63% |
| 2008 Q3 | 143.16 Million USD | -5.24% |
| 2008 Q1 | 159.53 Million USD | -4.53% |
| 2008 Q4 | 128.77 Million USD | -10.05% |
| 2008 Q2 | 151.08 Million USD | -5.3% |
| 2008 FY | 128.77 Million USD | -22.94% |
| 2007 FY | 167.09 Million USD | 180.15% |
| 2007 Q3 | 124.83 Million USD | -5.13% |
| 2007 Q2 | 131.58 Million USD | 80.13% |
| 2007 Q1 | 73.04 Million USD | 22.47% |
| 2007 Q4 | 167.09 Million USD | 33.86% |
| 2006 FY | 59.64 Million USD | 108.04% |
| 2006 Q4 | 59.64 Million USD | 0.0% |
| 2005 FY | 28.66 Million USD | 0.0% |
| 2005 Q4 | 28.66 Million USD | 0.0% |
| 2003 FY | 501 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Editas Medicine, Inc. | 499.15 Million USD | -55.84% |
| Dynavax Technologies Corporation | 997.09 Million USD | 21.985% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 44.791% |
| Perrigo Company plc | 10.8 Billion USD | 92.803% |
| Illumina, Inc. | 10.11 Billion USD | 92.307% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.212% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 0.317% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.04% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 97.085% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -249.6% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 97.649% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -1084.168% |
| Waters Corporation | 4.62 Billion USD | 83.188% |
| Biogen Inc. | 26.84 Billion USD | 97.102% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -370.53% |
| Evolus, Inc. | 188.99 Million USD | -311.581% |
| Adicet Bio, Inc. | 207.29 Million USD | -275.253% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -518.13% |
| bluebird bio, Inc. | 619.16 Million USD | -25.635% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -277.986% |
| FibroGen, Inc. | 423.52 Million USD | -83.666% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 92.773% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -2651.377% |
| Homology Medicines, Inc. | 47.05 Million USD | -1553.059% |
| Geron Corporation | 394.07 Million USD | -97.393% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 79.689% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 35.106% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -111.099% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 40.208% |
| Zoetis Inc. | 14.28 Billion USD | 94.555% |
| Abeona Therapeutics Inc. | 64 Million USD | -1115.4% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 76.818% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 88.63% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 96.578% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -1290.338% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 73.985% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -370.007% |
| Verastem, Inc. | 149.71 Million USD | -419.563% |
| Nektar Therapeutics | 398.03 Million USD | -95.431% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -32.239% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -294.053% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 76.172% |
| OPKO Health, Inc. | 2.01 Billion USD | 61.332% |
| Exelixis, Inc. | 2.94 Billion USD | 73.563% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 76.076% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -25.158% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -403.854% |
| uniQure N.V. | 831.68 Million USD | 6.47% |
| Imunon, Inc. | 21.91 Million USD | -3449.035% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 25.863% |
| Insmed Incorporated | 1.32 Billion USD | 41.506% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 55.121% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 16.992% |
| TG Therapeutics, Inc. | 329.58 Million USD | -136.017% |
| Incyte Corporation | 6.78 Billion USD | 88.53% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 57.606% |